Gossamer Bio files Form D for $150 million offering of rights to acquire securities
The San Diego biotechnology company reported $25 million sold so far to 38 investors, with $125 million remaining under the notice.
Gossamer Bio, Inc. filed a Form D with the SEC disclosing a new securities offering with a first sale date of August 20, 2026. The filing is marked as a New Notice with a date of first sale of 2026-08-20.1
The offering covers an option, warrant or other right to acquire another security, along with the security to be acquired upon exercise of that option, warrant or other right.1 The company stated that this offering is not tied to a merger, acquisition, or similar deal.
Financial terms disclosed in the filing show a total offering amount of $150,000,000, with $25,000,000 already sold and $125,000,000 remaining to be sold.1 The company reported 38 total investors who have already invested in the offering.1
The filing claims an exemption under Rule 506(b)1 of Regulation D. Gossamer said it does not intend this offering to last more than one year.1
Sales compensation is listed for two firms. Leerink Partners LLC, based in Boston, and Cantor Fitzgerald & Co., based in New York, are named as recipients of sales compensation, with Leerink authorized to solicit in all states and foreign jurisdictions and Cantor Fitzgerald authorized to solicit in all states.1
The company estimated sales commissions of $1,375,000, with no finders' fees reported.1 Gossamer indicated no portion of the gross proceeds is designated for payments to executive officers, directors, or promoters named in the filing.1
The notice was signed by Bryan Giraudo, listed as COO and CFO, on 2026-09-04.1 The filing lists the company's principal place of business as 3115 Merryfield Row, Suite 120, San Diego, California, 92121.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.